Global Anti Inflammatory Cytokines Market
Global Anti Inflammatory Cytokines Market

Anti Inflammatory Cytokines Comprehensive Study by Application (Graft-vs-host disease, Cystic Fibrosis, Cardiovascular diseases, Adipose tissue metabolism and obesity, Osteoarthritis, Atherosclerosis, Cancer, Infectious diseases, Others), Drug (Interleukin-1 receptor antagonist, Interleukin-4, Interleukin-6, Interleukin-10, Interleukin-11, Interleukin-13), Route of Administration (Oral, Intravenous, Others) Players and Region - Global Market Outlook to 2026

Anti Inflammatory Cytokines Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 206 Pages 217 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Industry Background:
The anti-inflammatory cytokines are a sequence of immunoregulatory molecules that control the proinflammatory cytokine reaction. Cytokines act jointly with specific cytokine inhibitors and solvable cytokine receptors to manage the human immune reaction. Anti-inflammatory cytokines have physiologic role in inflammation and pathologic role in systemic inflammatory states are increasingly recognized. Major anti-inflammatory cytokines include interleukin (IL)-1 receptor antagonist, IL-4, IL-6, IL-10, IL-11, and IL-13. According to the National Cancer Institute, diagnose is estimated over 1 million cases of cancer within the U.S. alone. Hence, the increasing treatment adoption rate is anticipated to boost global anti-inflammatory cytokines market growth within the coming decade. The changing lifestyle patterns have contributed to the prevalence of cancer and boost the anti-inflammatory market growth. As an example, consistent with the planet Health Organization (WHO) there have been total of 19.2 million new cases diagnosed for cancer across the world.This growth is primarily driven by Increasing Investments towards Healthcare Infrastructure and Research and Development Activities for Anti-Inflammatory Cytokines.

Globally, a noticeable market trend is evident Rising Number Of Cancer Patients Receiving Treatment. Major Players, such as Merck KGaA (Germany), Eli Lilly and Company (United States), Pfizer Inc. (United States), Sanofi S.A. (France), Novartis AG (Switzerland), Hoffmann-La Roche Ltd. (Switzerland), Lonza Group Ltd. (Switzerland), Thermo Fisher Scientific (United States), Meridian Bioscience Inc. (United States), Abcam PLC (United Kingdom), GenScript Biotech Corp (United States) and Randox Laboratories (United Kingdom) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In January 2021, Emergent BioSolutions and Humanigen have signed an agreement for development and manufacturing of drug called Lenzilumab. This drug is designed to prevent and treat an immune hyper-response of the cytokine storm. and In January 2021, Tetra Bio-pharma received approval from the U.S. Food and Drug Administration (FDA) to begin its Phase 1 trial with human subjects for its investigational therapeutic drug

Market Drivers
  • Increasing Investments towards Healthcare Infrastructure
  • Research and Development Activities for Anti-Inflammatory Cytokines

Market Trend
  • Rising Number Of Cancer Patients Receiving Treatment


Opportunities
The Increasing Rate of Approval and Commercialization of Biopharmaceutical Drugs and Increase in Awareness of Therapeutic Options Available for Cancer and Related Disorders
Challenges
Stringent Regulatory Requirements for Drug Approval

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Anti Inflammatory Cytokines Study Sheds Light on
— The Anti Inflammatory Cytokines Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Anti Inflammatory Cytokines industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Anti Inflammatory Cytokines industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Frequently Asked Questions (FAQ):

1. What is the growth rate predicted for the Global Anti Inflammatory Cytokines Market?
The Anti Inflammatory Cytokines market is expected to see a CAGR of % during projected year 2020 to 2026.

2. Who are the top performing companies in Anti Inflammatory Cytokines Market?
Top performing companies in the Global Anti Inflammatory Cytokines market are Merck KGaA (Germany), Eli Lilly and Company (United States), Pfizer Inc. (United States), Sanofi S.A. (France), Novartis AG (Switzerland), Hoffmann-La Roche Ltd. (Switzerland), Lonza Group Ltd. (Switzerland), Thermo Fisher Scientific (United States), Meridian Bioscience Inc. (United States), Abcam PLC (United Kingdom), GenScript Biotech Corp (United States) and Randox Laboratories (United Kingdom), to name a few.

3. Which region dominated the worldwide market for Anti Inflammatory Cytokines in 2020?
is dominating the Anti Inflammatory Cytokines Market.
Report Objectives / Segmentation Covered
By Application
  • Graft-vs-host disease
  • Cystic Fibrosis
  • Cardiovascular diseases
  • Adipose tissue metabolism and obesity
  • Osteoarthritis
  • Atherosclerosis
  • Cancer
  • Infectious diseases
  • Others
By Drug
  • Interleukin-1 receptor antagonist
  • Interleukin-4
  • Interleukin-6
  • Interleukin-10
  • Interleukin-11
  • Interleukin-13

By Route of Administration
  • Oral
  • Intravenous
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Investments towards Healthcare Infrastructure
      • 3.2.2. Research and Development Activities for Anti-Inflammatory Cytokines
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Requirements for Drug Approval
    • 3.4. Market Trends
      • 3.4.1. Rising Number Of Cancer Patients Receiving Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti Inflammatory Cytokines, by Application, Drug, Route of Administration and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Anti Inflammatory Cytokines (Value)
      • 5.2.1. Global Anti Inflammatory Cytokines by: Application (Value)
        • 5.2.1.1. Graft-vs-host disease
        • 5.2.1.2. Cystic Fibrosis
        • 5.2.1.3. Cardiovascular diseases
        • 5.2.1.4. Adipose tissue metabolism and obesity
        • 5.2.1.5. Osteoarthritis
        • 5.2.1.6. Atherosclerosis
        • 5.2.1.7. Cancer
        • 5.2.1.8. Infectious diseases
        • 5.2.1.9. Others
      • 5.2.2. Global Anti Inflammatory Cytokines by: Drug (Value)
        • 5.2.2.1. Interleukin-1 receptor antagonist
        • 5.2.2.2. Interleukin-4
        • 5.2.2.3. Interleukin-6
        • 5.2.2.4. Interleukin-10
        • 5.2.2.5. Interleukin-11
        • 5.2.2.6. Interleukin-13
      • 5.2.3. Global Anti Inflammatory Cytokines by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Intravenous
        • 5.2.3.3. Others
      • 5.2.4. Global Anti Inflammatory Cytokines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Anti Inflammatory Cytokines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck KGaA (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Eli Lilly and Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sanofi S.A. (France)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novartis AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Lonza Group Ltd. (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Thermo Fisher Scientific (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Meridian Bioscience Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Abcam PLC (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. GenScript Biotech Corp (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Randox Laboratories (United Kingdom)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Anti Inflammatory Cytokines Sale, by Application, Drug, Route of Administration and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Anti Inflammatory Cytokines (Value)
      • 7.2.1. Global Anti Inflammatory Cytokines by: Application (Value)
        • 7.2.1.1. Graft-vs-host disease
        • 7.2.1.2. Cystic Fibrosis
        • 7.2.1.3. Cardiovascular diseases
        • 7.2.1.4. Adipose tissue metabolism and obesity
        • 7.2.1.5. Osteoarthritis
        • 7.2.1.6. Atherosclerosis
        • 7.2.1.7. Cancer
        • 7.2.1.8. Infectious diseases
        • 7.2.1.9. Others
      • 7.2.2. Global Anti Inflammatory Cytokines by: Drug (Value)
        • 7.2.2.1. Interleukin-1 receptor antagonist
        • 7.2.2.2. Interleukin-4
        • 7.2.2.3. Interleukin-6
        • 7.2.2.4. Interleukin-10
        • 7.2.2.5. Interleukin-11
        • 7.2.2.6. Interleukin-13
      • 7.2.3. Global Anti Inflammatory Cytokines by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Intravenous
        • 7.2.3.3. Others
      • 7.2.4. Global Anti Inflammatory Cytokines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti Inflammatory Cytokines: by Application(USD Million)
  • Table 2. Anti Inflammatory Cytokines Graft-vs-host disease , by Region USD Million (2015-2020)
  • Table 3. Anti Inflammatory Cytokines Cystic Fibrosis , by Region USD Million (2015-2020)
  • Table 4. Anti Inflammatory Cytokines Cardiovascular diseases , by Region USD Million (2015-2020)
  • Table 5. Anti Inflammatory Cytokines Adipose tissue metabolism and obesity , by Region USD Million (2015-2020)
  • Table 6. Anti Inflammatory Cytokines Osteoarthritis , by Region USD Million (2015-2020)
  • Table 7. Anti Inflammatory Cytokines Atherosclerosis , by Region USD Million (2015-2020)
  • Table 8. Anti Inflammatory Cytokines Cancer , by Region USD Million (2015-2020)
  • Table 9. Anti Inflammatory Cytokines Infectious diseases , by Region USD Million (2015-2020)
  • Table 10. Anti Inflammatory Cytokines Others , by Region USD Million (2015-2020)
  • Table 11. Anti Inflammatory Cytokines: by Drug(USD Million)
  • Table 12. Anti Inflammatory Cytokines Interleukin-1 receptor antagonist , by Region USD Million (2015-2020)
  • Table 13. Anti Inflammatory Cytokines Interleukin-4 , by Region USD Million (2015-2020)
  • Table 14. Anti Inflammatory Cytokines Interleukin-6 , by Region USD Million (2015-2020)
  • Table 15. Anti Inflammatory Cytokines Interleukin-10 , by Region USD Million (2015-2020)
  • Table 16. Anti Inflammatory Cytokines Interleukin-11 , by Region USD Million (2015-2020)
  • Table 17. Anti Inflammatory Cytokines Interleukin-13 , by Region USD Million (2015-2020)
  • Table 18. Anti Inflammatory Cytokines: by Route of Administration(USD Million)
  • Table 19. Anti Inflammatory Cytokines Oral , by Region USD Million (2015-2020)
  • Table 20. Anti Inflammatory Cytokines Intravenous , by Region USD Million (2015-2020)
  • Table 21. Anti Inflammatory Cytokines Others , by Region USD Million (2015-2020)
  • Table 22. South America Anti Inflammatory Cytokines, by Country USD Million (2015-2020)
  • Table 23. South America Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 24. South America Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 25. South America Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 26. Brazil Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 27. Brazil Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 28. Brazil Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 29. Argentina Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 30. Argentina Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 31. Argentina Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 32. Rest of South America Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 33. Rest of South America Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 34. Rest of South America Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 35. Asia Pacific Anti Inflammatory Cytokines, by Country USD Million (2015-2020)
  • Table 36. Asia Pacific Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 37. Asia Pacific Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 38. Asia Pacific Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 39. China Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 40. China Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 41. China Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 42. Japan Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 43. Japan Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 44. Japan Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 45. India Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 46. India Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 47. India Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 48. South Korea Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 49. South Korea Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 50. South Korea Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 51. Taiwan Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 52. Taiwan Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 53. Taiwan Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 54. Australia Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 55. Australia Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 56. Australia Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 57. Rest of Asia-Pacific Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 60. Europe Anti Inflammatory Cytokines, by Country USD Million (2015-2020)
  • Table 61. Europe Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 62. Europe Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 63. Europe Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 64. Germany Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 65. Germany Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 66. Germany Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 67. France Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 68. France Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 69. France Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 70. Italy Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 71. Italy Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 72. Italy Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 73. United Kingdom Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 74. United Kingdom Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 75. United Kingdom Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 76. Netherlands Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 77. Netherlands Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 78. Netherlands Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 79. Rest of Europe Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 80. Rest of Europe Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 81. Rest of Europe Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 82. MEA Anti Inflammatory Cytokines, by Country USD Million (2015-2020)
  • Table 83. MEA Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 84. MEA Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 85. MEA Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 86. Middle East Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 87. Middle East Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 88. Middle East Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 89. Africa Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 90. Africa Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 91. Africa Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 92. North America Anti Inflammatory Cytokines, by Country USD Million (2015-2020)
  • Table 93. North America Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 94. North America Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 95. North America Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 96. United States Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 97. United States Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 98. United States Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 99. Canada Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 100. Canada Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 101. Canada Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 102. Mexico Anti Inflammatory Cytokines, by Application USD Million (2015-2020)
  • Table 103. Mexico Anti Inflammatory Cytokines, by Drug USD Million (2015-2020)
  • Table 104. Mexico Anti Inflammatory Cytokines, by Route of Administration USD Million (2015-2020)
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Company Basic Information, Sales Area and Its Competitors
  • Table 113. Company Basic Information, Sales Area and Its Competitors
  • Table 114. Company Basic Information, Sales Area and Its Competitors
  • Table 115. Company Basic Information, Sales Area and Its Competitors
  • Table 116. Company Basic Information, Sales Area and Its Competitors
  • Table 117. Anti Inflammatory Cytokines: by Application(USD Million)
  • Table 118. Anti Inflammatory Cytokines Graft-vs-host disease , by Region USD Million (2021-2026)
  • Table 119. Anti Inflammatory Cytokines Cystic Fibrosis , by Region USD Million (2021-2026)
  • Table 120. Anti Inflammatory Cytokines Cardiovascular diseases , by Region USD Million (2021-2026)
  • Table 121. Anti Inflammatory Cytokines Adipose tissue metabolism and obesity , by Region USD Million (2021-2026)
  • Table 122. Anti Inflammatory Cytokines Osteoarthritis , by Region USD Million (2021-2026)
  • Table 123. Anti Inflammatory Cytokines Atherosclerosis , by Region USD Million (2021-2026)
  • Table 124. Anti Inflammatory Cytokines Cancer , by Region USD Million (2021-2026)
  • Table 125. Anti Inflammatory Cytokines Infectious diseases , by Region USD Million (2021-2026)
  • Table 126. Anti Inflammatory Cytokines Others , by Region USD Million (2021-2026)
  • Table 127. Anti Inflammatory Cytokines: by Drug(USD Million)
  • Table 128. Anti Inflammatory Cytokines Interleukin-1 receptor antagonist , by Region USD Million (2021-2026)
  • Table 129. Anti Inflammatory Cytokines Interleukin-4 , by Region USD Million (2021-2026)
  • Table 130. Anti Inflammatory Cytokines Interleukin-6 , by Region USD Million (2021-2026)
  • Table 131. Anti Inflammatory Cytokines Interleukin-10 , by Region USD Million (2021-2026)
  • Table 132. Anti Inflammatory Cytokines Interleukin-11 , by Region USD Million (2021-2026)
  • Table 133. Anti Inflammatory Cytokines Interleukin-13 , by Region USD Million (2021-2026)
  • Table 134. Anti Inflammatory Cytokines: by Route of Administration(USD Million)
  • Table 135. Anti Inflammatory Cytokines Oral , by Region USD Million (2021-2026)
  • Table 136. Anti Inflammatory Cytokines Intravenous , by Region USD Million (2021-2026)
  • Table 137. Anti Inflammatory Cytokines Others , by Region USD Million (2021-2026)
  • Table 138. South America Anti Inflammatory Cytokines, by Country USD Million (2021-2026)
  • Table 139. South America Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 140. South America Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 141. South America Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 142. Brazil Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 143. Brazil Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 144. Brazil Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 145. Argentina Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 146. Argentina Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 147. Argentina Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 148. Rest of South America Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 149. Rest of South America Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 150. Rest of South America Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 151. Asia Pacific Anti Inflammatory Cytokines, by Country USD Million (2021-2026)
  • Table 152. Asia Pacific Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 153. Asia Pacific Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 154. Asia Pacific Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 155. China Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 156. China Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 157. China Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 158. Japan Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 159. Japan Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 160. Japan Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 161. India Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 162. India Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 163. India Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 164. South Korea Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 165. South Korea Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 166. South Korea Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 167. Taiwan Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 168. Taiwan Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 169. Taiwan Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 170. Australia Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 171. Australia Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 172. Australia Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 173. Rest of Asia-Pacific Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 174. Rest of Asia-Pacific Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 175. Rest of Asia-Pacific Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 176. Europe Anti Inflammatory Cytokines, by Country USD Million (2021-2026)
  • Table 177. Europe Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 178. Europe Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 179. Europe Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 180. Germany Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 181. Germany Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 182. Germany Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 183. France Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 184. France Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 185. France Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 186. Italy Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 187. Italy Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 188. Italy Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 189. United Kingdom Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 190. United Kingdom Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 191. United Kingdom Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 192. Netherlands Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 193. Netherlands Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 194. Netherlands Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 195. Rest of Europe Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 196. Rest of Europe Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 197. Rest of Europe Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 198. MEA Anti Inflammatory Cytokines, by Country USD Million (2021-2026)
  • Table 199. MEA Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 200. MEA Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 201. MEA Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 202. Middle East Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 203. Middle East Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 204. Middle East Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 205. Africa Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 206. Africa Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 207. Africa Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 208. North America Anti Inflammatory Cytokines, by Country USD Million (2021-2026)
  • Table 209. North America Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 210. North America Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 211. North America Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 212. United States Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 213. United States Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 214. United States Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 215. Canada Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 216. Canada Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 217. Canada Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 218. Mexico Anti Inflammatory Cytokines, by Application USD Million (2021-2026)
  • Table 219. Mexico Anti Inflammatory Cytokines, by Drug USD Million (2021-2026)
  • Table 220. Mexico Anti Inflammatory Cytokines, by Route of Administration USD Million (2021-2026)
  • Table 221. Research Programs/Design for This Report
  • Table 222. Key Data Information from Secondary Sources
  • Table 223. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti Inflammatory Cytokines: by Application USD Million (2015-2020)
  • Figure 5. Global Anti Inflammatory Cytokines: by Drug USD Million (2015-2020)
  • Figure 6. Global Anti Inflammatory Cytokines: by Route of Administration USD Million (2015-2020)
  • Figure 7. South America Anti Inflammatory Cytokines Share (%), by Country
  • Figure 8. Asia Pacific Anti Inflammatory Cytokines Share (%), by Country
  • Figure 9. Europe Anti Inflammatory Cytokines Share (%), by Country
  • Figure 10. MEA Anti Inflammatory Cytokines Share (%), by Country
  • Figure 11. North America Anti Inflammatory Cytokines Share (%), by Country
  • Figure 12. Global Anti Inflammatory Cytokines share by Players 2020 (%)
  • Figure 13. Global Anti Inflammatory Cytokines share by Players (Top 3) 2020(%)
  • Figure 14. Global Anti Inflammatory Cytokines share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Merck KGaA (Germany) Revenue: by Geography 2020
  • Figure 18. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 19. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 20. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 21. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 22. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 23. Sanofi S.A. (France) Revenue: by Geography 2020
  • Figure 24. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. Novartis AG (Switzerland) Revenue: by Geography 2020
  • Figure 26. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 27. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 28. Lonza Group Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 29. Lonza Group Ltd. (Switzerland) Revenue: by Geography 2020
  • Figure 30. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 31. Thermo Fisher Scientific (United States) Revenue: by Geography 2020
  • Figure 32. Meridian Bioscience Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Meridian Bioscience Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Abcam PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 35. Abcam PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 36. GenScript Biotech Corp (United States) Revenue, Net Income and Gross profit
  • Figure 37. GenScript Biotech Corp (United States) Revenue: by Geography 2020
  • Figure 38. Randox Laboratories (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 39. Randox Laboratories (United Kingdom) Revenue: by Geography 2020
  • Figure 40. Global Anti Inflammatory Cytokines: by Application USD Million (2021-2026)
  • Figure 41. Global Anti Inflammatory Cytokines: by Drug USD Million (2021-2026)
  • Figure 42. Global Anti Inflammatory Cytokines: by Route of Administration USD Million (2021-2026)
  • Figure 43. South America Anti Inflammatory Cytokines Share (%), by Country
  • Figure 44. Asia Pacific Anti Inflammatory Cytokines Share (%), by Country
  • Figure 45. Europe Anti Inflammatory Cytokines Share (%), by Country
  • Figure 46. MEA Anti Inflammatory Cytokines Share (%), by Country
  • Figure 47. North America Anti Inflammatory Cytokines Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Merck KGaA (Germany)
  • Eli Lilly and Company (United States)
  • Pfizer Inc. (United States)
  • Sanofi S.A. (France)
  • Novartis AG (Switzerland)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • Lonza Group Ltd. (Switzerland)
  • Thermo Fisher Scientific (United States)
  • Meridian Bioscience Inc. (United States)
  • Abcam PLC (United Kingdom)
  • GenScript Biotech Corp (United States)
  • Randox Laboratories (United Kingdom)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation